Tislelizumab plus chemo before surgery or radiation for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if adding the immunotherapy drug tislelizumab to standard chemotherapy before surgery or radiation can improve outcomes for people with resectable esophageal squamous cell carcinoma. It is designed for patients whose cancer is in the chest and has not spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a type of esophageal cancer called squamous cell carcinoma.
- Your cancer is in the middle part of the esophagus and is at a stage where it can be removed with surgery (cT2N+ or cT3-4aNanyM0).
- You are in generally good health (ECOG score 0 or 1).
- Your blood counts, kidney function, and liver function are within certain normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with standard chemotherapy given before and after surgery for esophageal cancer. It aims to see if this approach can improve treatment outcomes for patients with a certain stage of the disease.
This trial tests a single immunotherapy drug (tislelizumab) given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if it can shrink the tumor and improve outcomes.
This trial tests a combination of treatments given before surgery to shrink tumors in patients with esophageal cancer that is considered too advanced for immediate surgery. The goal is to make surgery possible and improve outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation, followed by surgery, for people with advanced esophageal cancer that cannot be removed right away. It aims to see if this approach can help shrink the tumor enough to allow surgery.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.